Go Pro
NASDAQ:LNSR

LENSAR Q2 2025 Earnings Report

LENSAR logo
$8.68 +0.24 (+2.84%)
As of 08/21/2026 04:00 PM Eastern

LENSAR EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

LENSAR Revenue Results

Actual Revenue
$11.36 million
Expected Revenue
$16.55 million
Beat/Miss
Missed by -$5.19 million
YoY Revenue Growth
N/A

LENSAR Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
7:00AM ET

LENSAR Earnings Headlines

LENSAR (NASDAQ:LNSR) Price Target Raised to $9.00
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investment of 17 million dollars. He is known for predicting the 2020 market crash with striking accuracy. Today he is hosting a free live demo of his newest AI-driven trading approach, showing how he analyzes market data without guesswork or speculation.tc pixel
Wall Street Zen Upgrades LENSAR (NASDAQ:LNSR) to "Hold"
LENSAR Inc
See More LENSAR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENSAR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENSAR and other key companies, straight to your email.

About LENSAR

LENSAR (NASDAQ:LNSR), headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. The company holds multiple patents related to its image-guided treatment planning and laser control algorithms. Clinical collaborations and peer-reviewed studies have supported the safety and efficacy of the LENSAR system, demonstrating improvements in procedural consistency and efficiency.

Operating across North America, Europe, the Asia-Pacific region and Latin America, LENSAR markets its laser platforms to hospitals, ambulatory surgery centers and specialty eye clinics. The company offers comprehensive training programs for ophthalmic surgeons, ongoing technical support and regular software upgrades to help practices integrate femtosecond laser technology. By maintaining a focused portfolio of ophthalmic solutions, LENSAR seeks to advance the standard of care in cataract surgery through continuous innovation and service excellence.

View LENSAR Profile